PTCT
PTC Therapeutics Inc
NASDAQ: PTCT · HEALTHCARE · BIOTECHNOLOGY
$76.85
+0.47% today
Updated 2026-06-05
Market cap
$6.23B
P/E ratio
—
P/S ratio
7.54x
EPS (TTM)
$-2.54
Dividend yield
—
52W range
$43 – $88
Volume
1.2M
PTC Therapeutics Inc (PTCT) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed PTCT price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$76.85
Today
Analyst consensus
$88.36
+14.98% · 12M
2030 Base
$49.91
-35.06% future
NPV today
$35.91
@ 7% WACC
14 analysts:
9 Buy3 Hold2 Sell
Management guidance
PTC raised FY2026 product revenue guidance to $750-850M (from prior guidance), with total revenue projected at $1.08-1.18B. CEO Matthew Klein emphasized strong Sephience launch momentum ($125M in Q1 2026 alone) and pipeline advancement in neurology (votoplam for Huntington's disease showing positive 24-month data). Management targets sustained growth from PKU franchise expansion globally and DMD royalty streams from Evrysdi partnership.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
PTCT · PTC Therapeutics Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$20.81
NPV today: $14.97
Base case (2030)
$49.91
NPV today: $35.91
Bull case (2030)
$166.32
NPV today: $119.68
WallStSmart.com
PTCT financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.1B | $1.5B | $1.9B | $2.2B | $2.6B |
| Revenue growth | 114.5% | 34.8% | 34.5% | 24.3% | 18.5% | 15.2% |
| Net margin | — | -1.1% | 2.5% | 5.4% | 7.5% | 8.9% |
| EPS | $7.61 | $-0.15 | $0.45 | $1.18 | $1.92 | $2.58 |
| Diluted shares | — | 84M | 86M | 87M | 88M | 89M |
| Net debt | — | $893.83M | $1.34B | $1.90B | $2.56B | $3.31B |
| P/S multiple | — | 3.0x | 3.0x | 3.0x | 3.0x | 3.0x |
| Implied price (base) | — | $29.62 | $37.63 | $43.54 | $47.49 | $49.91 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.6B |
| P/S multiple | 2.0x | 3.0x | 7.0x |
| Diluted shares | 89M | 89M | 89M |
| Net debt | $3.31B | $3.31B | $3.31B |
| Implied P/E † | 8x | 19x | 65x |
| 2030 Price | $20.81 | $49.91 | $166.32 |
| NPV @ 7% | $14.97 | $35.91 | $119.68 |
† Implied P/E: Multiples remain elevated across all three scenarios because PTCT is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $49.91 base case
PTCT catalysts and risks
Growth catalysts
+ Sephience (sepiapterin) global PKU launch acceleration - $125M in Q1 2026, targeting $750-850M product revenue in FY2026
+ Votoplam (Huntington's disease) Phase 3 positive interim data at 24 months; potential NDA submission in 2027-2028
+ Vatiquinone (Friedreich's ataxia) open-label study initiation; $50M Novartis milestone payment in 2026
+ Evrysdi (SMA) royalty revenue expansion and market penetration in underpenetrated geographies
+ Pipeline advancement in neurology addressing large TAM; potential additional FDA approvals through 2028
Key risks
- Revenue cliff risk: TTM revenue declined 53.3% YoY to $827M due to Q1 2026 comparability challenges; Q1 2026 showed -76.8% QoQ decline indicating prior period was exceptional (Q1 2025 = $1.2B revenue, $867M net income). Sustainability of Sephience ramp is critical.
- Profitability burden: Persistent negative net margins (-22.6% TTM) despite revenue scale; company remains unprofitable on GAAP basis with negative shareholders' equity. High cash burn despite $1.89B liquidity.
- Clinical execution risk: Votoplam in competitive Huntington's market (CTX program competitor); vatiquinone in rare disease with smaller addressable population. Pipeline dependent on timely data and regulatory approval.
- Patent/generic cliff: Evrysdi royalty base faces generic competition risk; Translarna NDA withdrawn in Feb 2026 due to FDA feedback on weak proof (material near-term revenue impact).
- Biotech funding/dilution risk: Negative equity and cash burn profile may require additional capital raises through 2028-2030, diluting shareholder value.
Methodology · PTC Therapeutics Inc 2030 stock forecast model
PTC Therapeutics Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (7% cumulative for PTCT by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($3.31B by 2030) |
| 3. Time value | NPV calculated using 7% WACC (CAPM: beta 0.526) |
| 4. Multiple framework | P/S compresses with scale: bear 2.0x / base 3.0x / bull 7.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
PTCT price target FAQ
What is the PTCT price target for 2030?
WallStSmart's PTC Therapeutics Inc 2030 base case is $49.91 per share, with a bull case of $166.32 and bear case of $20.81. The NPV of the base case discounted to today at 7% WACC is $35.91.
How is the PTC Therapeutics Inc 2030 stock forecast calculated?
The PTCT 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the PTCT price target account for dilution?
PTC Therapeutics Inc is projected to grow diluted share count from 83M to 89M by 2030 (a 7% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 7%.
What is the analyst consensus on PTCT stock?
14 analysts cover PTCT with an average 12-month price target of $88.36. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.